Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Commercial Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,719 |
Reported balance
After 2026-10-12 transaction · row 1
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 3,288 · Balance 48,719 F1: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F2: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 14, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,288 | $33.64 | $110,608.32 |
DisclosureSEC source: 0001628280-26-065870 · wk-form4_1792008382.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,719 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.52 to $34.03, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 00:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,034 | $34.20 | $35,362.80 |
DisclosureSEC source: 0001628280-26-064267 · wk-form4_1790886076.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,007 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.090 to $34.525, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 29, 2026 Filed Oct 2, 2026 00:21 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,543 | $35.50 | $196,765.41 |
DisclosureSEC source: 0001628280-26-064267 · wk-form4_1790886076.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,041 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.010 to $35.935, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,294 | $35.14 | $115,757.75 |
DisclosureSEC source: 0001628280-26-062255 · wk-form4_1789590027.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,584 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.000 to $35.380, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2026 Filed Sep 16, 2026 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,306 | $32.32 | $106,863.14 |
DisclosureSEC source: 0001628280-26-062255 · wk-form4_1789590027.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,878 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 28, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.180 to $32.445, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,730 | $32.81 | $56,761.30 |
DisclosureSEC source: 0001628280-26-060089 · wk-form4_1788379622.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,184 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.39 to $33.17, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 25, 2026 Filed Aug 27, 2026 20:38 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9,050 | $35.04 | $317,112.00 |
DisclosureSEC source: 0001628280-26-059272 · wk-form4_1787863108.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,914 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.14, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:11 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,730 | $29.59 | $51,190.70 |
DisclosureSEC source: 0001628280-26-057949 · wk-form4_1787170306.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,964 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $29.21 to $30.01, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2026 Filed Aug 4, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,730 | $28.25 | $48,872.50 |
DisclosureSEC source: 0001628280-26-052648 · wk-form4_1785875769.xml · nonDerivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,995 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $28.030 to $28.630, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,891 | $30.26 | $57,229.22 |
DisclosureSEC source: 0001628280-26-052648 · wk-form4_1785875769.xml · nonDerivative · entry 3 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,725 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.150 to $30.645, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 7,270 | $29.58 | $215,039.33 |
DisclosureSEC source: 0001628280-26-052648 · wk-form4_1785875769.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,616 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $29.150 to $30.130, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:36 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,149 | $28.84 | $235,033.46 |
DisclosureSEC source: 0001628280-26-052648 · wk-form4_1785875769.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,886 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.150 to $29.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 11,210 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001628280-26-038072 · wk-form4_1779825996.xml · derivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,210 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:06 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 11,210 | $3.38 | $37,889.80 |
DisclosureSEC source: 0001628280-26-038072 · wk-form4_1779825996.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2026 Filed Mar 16, 2026 20:07 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 20,863 | $25.24 | $526,582.12 |
DisclosureSEC source: 0001628280-26-018156 · wk-form4_1773691674.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,825 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 10, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.90 to $25.70, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 11,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · derivative · entry 6 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,878 Underlying: Common Stock · 11,960 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026. F5 · derivative.expiration_date: On March 4, 2025, the Reporting Person was granted 47,838 RSUs which vest in four equal installments beginning on March 4, 2026. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 13,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · derivative · entry 5 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,621 Underlying: Common Stock · 13,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 55,243 RSUs which vest in four equal installments beginning on March 4, 2025. F4 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 55,243 RSUs which vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 10,399 | $28.17 | $292,939.83 |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · nonDerivative · entry 3 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,688 Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 25,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 48,367 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,367 Underlying: Common Stock · 48,367 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. F3 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 03, 2027. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:18 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 3,716 | $27.57 | $102,450.12 |
DisclosureSEC source: 0001628280-26-015355 · wk-form4_1772749118.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,316 F1 · shares: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the delivery of vested performance stock units reported on January 12, 2026. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantPerformance-Based Stock Unit · Derivative | 9,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001856542-26-000002 · form4-01142026_040104.xml · derivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,207 Underlying: Common Stock · 9,207 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F2 · derivative.exercise_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. F2 · derivative.expiration_date: Each PSU represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the 2024 PSUs which will vest subject to the achievement of certain milestones. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantCommon Stock | 9,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001856542-26-000002 · form4-01142026_040104.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,032 F1 · shares: Represents 50% of the Performance-Based Stock Units ("PSUs") granted on March 4, 2024 ("2024 PSUs") that vested based on the satisfaction of certain performance criteria as certified by the board of directors of the Issuer on January 12, 2026. Read SEC document |
| December 11, 2025 Filed Dec 15, 2025 21:09 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 13,200 | $37.48 | $494,736.00 |
DisclosureSEC source: 0001628280-25-057016 · wk-form4_1765832977.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,825 F1 · price: This transaction was executed in multiple trades at prices ranging from $37.31 to $37.72, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 6,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · derivative · entry 6 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,170 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. F4 · derivative.expiration_date: On December 10, 2021, the Reporting Person was granted 24,679 RSUs which vest in four equal installments beginning on December 10, 2022. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 2,490 | $38.02 | $94,669.80 |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · nonDerivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,025 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 6,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · nonDerivative · entry 3 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 15,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · derivative · entry 5 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,961 Underlying: Common Stock · 15,961 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On December 9, 2022, the Reporting Person was granted 63,844 RSUs which vest in four equal installments beginning on December 9, 2023. F3 · derivative.expiration_date: On December 9, 2022, the Reporting Person was granted 63,844 RSUs which vest in four equal installments beginning on December 9, 2023. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 6,441 | $38.25 | $246,368.25 |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,345 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:44 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 15,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-056625 · wk-form4_1765496679.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F2 · balance_after: The amount includes 2,230 shares previously held by the Tobin W and Susan M Juvenal Family Revocable Trust, which were distributed to the Reporting Person on February 5, 2025, and are now owned directly. Read SEC document |
| November 24, 2025 Filed Aug 6, 2026 20:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,301 | $38.39 | $49,945.39 |
DisclosureSEC source: 0001628280-26-054338 · wk-form4_1786047286.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,694 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 4,693 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001628280-25-053812 · wk-form4_1764019447.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,210 Underlying: Common Stock · 4,693 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F5 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 4,693 | $35.58 | $166,976.94 |
DisclosureSEC source: 0001628280-25-053812 · wk-form4_1764019447.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,595 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $35.40 to $35.85, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Reflects an adjustment of 68 shares to the number of shares beneficially owned following a reconciliation of the Reporting Person's records. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:24 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 4,693 | $3.38 | $15,862.34 |
DisclosureSEC source: 0001628280-25-053812 · wk-form4_1764019447.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F2 · balance_after: Reflects an adjustment of 68 shares to the number of shares beneficially owned following a reconciliation of the Reporting Person's records. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $35.40 | $7,080.00 |
DisclosureSEC source: 0001628280-25-052019 · wk-form4_1763068093.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,827 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F3 · price: This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · derivative · entry 7 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,903 Underlying: Common Stock · 200 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F5 · kind: The exercise of the options was inadvertently omitted from the original Form 4 filing and is now being reported in this Amendment. F6 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $35.40 | $7,080.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · nonDerivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,527 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F3 · price: This transaction was executed at a price of $35.40. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 200 | $3.38 | $676.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · nonDerivative · entry 3 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:08 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $35.39 | $17,695.00 |
DisclosureSEC source: 0001628280-25-052019 · wk-form4_1763068093.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,027 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 500 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · derivative · entry 6 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,103 Underlying: Common Stock · 500 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F5 · kind: The exercise of the options was inadvertently omitted from the original Form 4 filing and is now being reported in this Amendment. F6 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 500 | $35.39 | $17,695.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,527 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.38 to $35.40, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2025 Filed Nov 14, 2025 21:09 UTC Amendment | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 500 | $3.38 | $1,690.00 |
DisclosureSEC source: 0001628280-25-052350 · wk-form4a_1763154587.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionPerformance-Based Stock Unit · Derivative | 10,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001856542-25-000003 · wk-form4_1755030624.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F2 · derivative.exercise_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. F2 · derivative.expiration_date: Each Performance-Based Stock Unit ("PSU") represents the right to receive one share of the Issuer's Common Stock. These PSUs represent the remaining 50% of the PSUs granted on December 23, 2022, which were all subject to time-based vesting and vested in full on the one-year anniversary of August 9, 2024. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 4,294 | $19.36 | $83,131.84 |
DisclosureSEC source: 0001856542-25-000003 · wk-form4_1755030624.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,527 Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 20:30 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 10,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001856542-25-000003 · wk-form4_1755030624.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionRestricted Stock Units · Derivative | 13,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000036 · wk-form4_1741295669.xml · derivative · entry 5 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,432 Underlying: Common Stock · 13,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 55,243 RSUs which vest in four equal installments beginning on March 4, 2025. F4 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 55,243 RSUs which vest in four equal installments beginning on March 4, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantRestricted Stock Units · Derivative | 47,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001447362-25-000036 · wk-form4_1741295669.xml · derivative · entry 4 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,838 Underlying: Common Stock · 47,838 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSU's vest in four equal annual installments beginning on March 04, 2026. F3 · derivative.expiration_date: The RSU's vest in four equal annual installments beginning on March 04, 2026. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Tax withholdingCommon Stock | 5,573 | $22.23 | $123,887.79 |
DisclosureSEC source: 0001447362-25-000036 · wk-form4_1741295669.xml · nonDerivative · entry 2 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,181 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,811 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001447362-25-000036 · wk-form4_1741295669.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 23:17 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,230 | $30.00 | $66,900.00 |
DisclosureSEC source: 0001447362-25-000004 · wk-form4_1736378220.xml · nonDerivative · entry 1 Juvenal Tobin W · CIK 0001856542 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,943 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 11, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.